Thrombosis and Bleeding in Patients with Vaccine-Induced Immune Thrombotic Thrombocytopenia: A Systematic Review of Published Cases

Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a highly prothrombotic reaction to COVID-19 (coronavirus disease 2019) adenoviral vector vaccines. Its distinct bleeding and thrombotic patterns compared with other platelet consumptive disorders remain unclear.  We performed a systematic...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Thrombosis and haemostasis Ročník 124; číslo 5; s. 423
Hlavní autoři: Clerici, Bianca, Pontisso, Eleonora, Aloise, Chiara, Peroni, Benedetta, Perricone, Rosaria, Pisetta, Chiara, Scavone, Mariangela, Birocchi, Simone, Podda, Gian Marco
Médium: Journal Article
Jazyk:angličtina
Vydáno: Germany 01.05.2024
Témata:
ISSN:2567-689X, 2567-689X
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a highly prothrombotic reaction to COVID-19 (coronavirus disease 2019) adenoviral vector vaccines. Its distinct bleeding and thrombotic patterns compared with other platelet consumptive disorders remain unclear.  We performed a systematic review of the literature (PubMed and Embase) up to July 31, 2022, including case reports and case series providing nonaggregate data of VITT patients. Accurate VITT diagnosis required fulfillment of the following criteria: (1) endorsement by the authors, (2) consistent vaccine type and timing, (3) presence of thrombocytopenia and thrombosis, (4) detection of anti-platelet factor 4 antibodies. Data are presented as frequencies with 95% confidence intervals (CIs) calculated with the exact binomial method.  We retrieved 143 eligible studies, describing 366 patients. Of 647 thrombotic events, 53% (95% CI: 49-56) were venous thromboses at unusual sites and 30% (95% CI: 27-34) were cerebral venous sinus thromboses (CVSTs). The ratio of venous-to-arterial events was 4.1. Thromboses in most sites were associated with at least another thrombotic event, with the exception of CVST and CNS arterial thrombosis (isolated in 49 and 39% of cases, respectively). Bleeding occurred in 36% (95% CI: 31-41) of patients; 68% (95% CI: 59-75) of bleeding events were intracranial hemorrhages (ICHs). Overall mortality was 24% (95% CI: 19-29), and 77% (95% CI: 58-90) in patients with isolated CVST complicated by ICH.  VITT displays a venous-to-arterial thrombosis ratio comparable to heparin-induced thrombocytopenia. However, VITT is characterized by a higher prevalence of CVST and ICH, which contribute to the increased bleeding frequency and mortality.
AbstractList Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a highly prothrombotic reaction to COVID-19 (coronavirus disease 2019) adenoviral vector vaccines. Its distinct bleeding and thrombotic patterns compared with other platelet consumptive disorders remain unclear.  We performed a systematic review of the literature (PubMed and Embase) up to July 31, 2022, including case reports and case series providing nonaggregate data of VITT patients. Accurate VITT diagnosis required fulfillment of the following criteria: (1) endorsement by the authors, (2) consistent vaccine type and timing, (3) presence of thrombocytopenia and thrombosis, (4) detection of anti-platelet factor 4 antibodies. Data are presented as frequencies with 95% confidence intervals (CIs) calculated with the exact binomial method.  We retrieved 143 eligible studies, describing 366 patients. Of 647 thrombotic events, 53% (95% CI: 49-56) were venous thromboses at unusual sites and 30% (95% CI: 27-34) were cerebral venous sinus thromboses (CVSTs). The ratio of venous-to-arterial events was 4.1. Thromboses in most sites were associated with at least another thrombotic event, with the exception of CVST and CNS arterial thrombosis (isolated in 49 and 39% of cases, respectively). Bleeding occurred in 36% (95% CI: 31-41) of patients; 68% (95% CI: 59-75) of bleeding events were intracranial hemorrhages (ICHs). Overall mortality was 24% (95% CI: 19-29), and 77% (95% CI: 58-90) in patients with isolated CVST complicated by ICH.  VITT displays a venous-to-arterial thrombosis ratio comparable to heparin-induced thrombocytopenia. However, VITT is characterized by a higher prevalence of CVST and ICH, which contribute to the increased bleeding frequency and mortality.
Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a highly prothrombotic reaction to COVID-19 (coronavirus disease 2019) adenoviral vector vaccines. Its distinct bleeding and thrombotic patterns compared with other platelet consumptive disorders remain unclear.INTRODUCTION Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a highly prothrombotic reaction to COVID-19 (coronavirus disease 2019) adenoviral vector vaccines. Its distinct bleeding and thrombotic patterns compared with other platelet consumptive disorders remain unclear. We performed a systematic review of the literature (PubMed and Embase) up to July 31, 2022, including case reports and case series providing nonaggregate data of VITT patients. Accurate VITT diagnosis required fulfillment of the following criteria: (1) endorsement by the authors, (2) consistent vaccine type and timing, (3) presence of thrombocytopenia and thrombosis, (4) detection of anti-platelet factor 4 antibodies. Data are presented as frequencies with 95% confidence intervals (CIs) calculated with the exact binomial method.METHODS We performed a systematic review of the literature (PubMed and Embase) up to July 31, 2022, including case reports and case series providing nonaggregate data of VITT patients. Accurate VITT diagnosis required fulfillment of the following criteria: (1) endorsement by the authors, (2) consistent vaccine type and timing, (3) presence of thrombocytopenia and thrombosis, (4) detection of anti-platelet factor 4 antibodies. Data are presented as frequencies with 95% confidence intervals (CIs) calculated with the exact binomial method. We retrieved 143 eligible studies, describing 366 patients. Of 647 thrombotic events, 53% (95% CI: 49-56) were venous thromboses at unusual sites and 30% (95% CI: 27-34) were cerebral venous sinus thromboses (CVSTs). The ratio of venous-to-arterial events was 4.1. Thromboses in most sites were associated with at least another thrombotic event, with the exception of CVST and CNS arterial thrombosis (isolated in 49 and 39% of cases, respectively). Bleeding occurred in 36% (95% CI: 31-41) of patients; 68% (95% CI: 59-75) of bleeding events were intracranial hemorrhages (ICHs). Overall mortality was 24% (95% CI: 19-29), and 77% (95% CI: 58-90) in patients with isolated CVST complicated by ICH.RESULTS We retrieved 143 eligible studies, describing 366 patients. Of 647 thrombotic events, 53% (95% CI: 49-56) were venous thromboses at unusual sites and 30% (95% CI: 27-34) were cerebral venous sinus thromboses (CVSTs). The ratio of venous-to-arterial events was 4.1. Thromboses in most sites were associated with at least another thrombotic event, with the exception of CVST and CNS arterial thrombosis (isolated in 49 and 39% of cases, respectively). Bleeding occurred in 36% (95% CI: 31-41) of patients; 68% (95% CI: 59-75) of bleeding events were intracranial hemorrhages (ICHs). Overall mortality was 24% (95% CI: 19-29), and 77% (95% CI: 58-90) in patients with isolated CVST complicated by ICH. VITT displays a venous-to-arterial thrombosis ratio comparable to heparin-induced thrombocytopenia. However, VITT is characterized by a higher prevalence of CVST and ICH, which contribute to the increased bleeding frequency and mortality.CONCLUSION VITT displays a venous-to-arterial thrombosis ratio comparable to heparin-induced thrombocytopenia. However, VITT is characterized by a higher prevalence of CVST and ICH, which contribute to the increased bleeding frequency and mortality.
Author Aloise, Chiara
Perricone, Rosaria
Birocchi, Simone
Podda, Gian Marco
Pontisso, Eleonora
Pisetta, Chiara
Clerici, Bianca
Peroni, Benedetta
Scavone, Mariangela
Author_xml – sequence: 1
  givenname: Bianca
  surname: Clerici
  fullname: Clerici, Bianca
  organization: Dipartimento di Scienze della Salute, Università degli Studi di Milano, Struttura Complessa di Medicina Generale II, Ospedale San Paolo, Milano, Italy
– sequence: 2
  givenname: Eleonora
  surname: Pontisso
  fullname: Pontisso, Eleonora
  organization: Dipartimento di Scienze della Salute, Università degli Studi di Milano, Struttura Complessa di Medicina Generale II, Ospedale San Paolo, Milano, Italy
– sequence: 3
  givenname: Chiara
  surname: Aloise
  fullname: Aloise, Chiara
  organization: Dipartimento di Scienze della Salute, Università degli Studi di Milano, Struttura Complessa di Medicina Generale II, Ospedale San Paolo, Milano, Italy
– sequence: 4
  givenname: Benedetta
  surname: Peroni
  fullname: Peroni, Benedetta
  organization: Dipartimento di Scienze della Salute, Università degli Studi di Milano, Struttura Complessa di Medicina Generale II, Ospedale San Paolo, Milano, Italy
– sequence: 5
  givenname: Rosaria
  surname: Perricone
  fullname: Perricone, Rosaria
  organization: Dipartimento di Scienze della Salute, Università degli Studi di Milano, Struttura Complessa di Medicina Generale II, Ospedale San Paolo, Milano, Italy
– sequence: 6
  givenname: Chiara
  surname: Pisetta
  fullname: Pisetta, Chiara
  organization: Dipartimento di Scienze della Salute, Università degli Studi di Milano, Struttura Complessa di Medicina Generale II, Ospedale San Paolo, Milano, Italy
– sequence: 7
  givenname: Mariangela
  surname: Scavone
  fullname: Scavone, Mariangela
  organization: Dipartimento di Scienze della Salute, Università degli Studi di Milano, Struttura Complessa di Medicina Generale II, Ospedale San Paolo, Milano, Italy
– sequence: 8
  givenname: Simone
  surname: Birocchi
  fullname: Birocchi, Simone
  organization: Dipartimento di Scienze della Salute, Università degli Studi di Milano, Struttura Complessa di Medicina Generale II, Ospedale San Paolo, Milano, Italy
– sequence: 9
  givenname: Gian Marco
  surname: Podda
  fullname: Podda, Gian Marco
  organization: Dipartimento di Scienze della Salute, Università degli Studi di Milano, Struttura Complessa di Medicina Generale II, Ospedale San Paolo, Milano, Italy
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38109906$$D View this record in MEDLINE/PubMed
BookMark eNpNkMtLAzEYxINUtFavHiVHL6t57CveavFRKFi0irfl2-RbG9jN1k3W0rP_uBVb8DQD85s5zAkZuNYhIeecXXGWJNc-YiyWEc-yjMv4gAxFkmZRmqv3wT9_RI5lzplSLB2S78Wya5uy9dZTcIbe1ojGug9qHZ1DsOiCp2sblvQNtLYOo6kzvUZDp03TO6S7frB6b_UmtCt0Fm7omL5sfMAGfuNn_LK4pm1F531ZW7_cjkzAoz8lhxXUHs92OiKv93eLyWM0e3qYTsazSEspQ4QGUCFXuhRVxYEDCMmSWHGFGMdpYtIK0jJPOCoAzQUwmaeJULnKjc4qI0bk8m931bWfPfpQNNZrrGtw2Pa-EGrbSFTM5Ba92KF92aApVp1toNsU--PED5AmcQQ
CitedBy_id crossref_primary_10_1080_21645515_2024_2363016
crossref_primary_10_1016_j_ajog_2024_04_028
crossref_primary_10_1016_j_ijid_2024_107095
crossref_primary_10_4081_btvb_2024_127
ContentType Journal Article
Copyright Thieme. All rights reserved.
Copyright_xml – notice: Thieme. All rights reserved.
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1055/s-0043-1777134
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
EISSN 2567-689X
ExternalDocumentID 38109906
Genre Systematic Review
Journal Article
GroupedDBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c333t-edae9e19cb2ff1a1aa23054919ee4465d6fa6b851e9aac12a0386529898dc7fd2
IEDL.DBID 7X8
ISICitedReferencesCount 4
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001126792000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 2567-689X
IngestDate Fri Jul 11 05:11:46 EDT 2025
Thu Apr 03 07:03:41 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 5
Language English
License Thieme. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c333t-edae9e19cb2ff1a1aa23054919ee4465d6fa6b851e9aac12a0386529898dc7fd2
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Undefined-1
ObjectType-Feature-3
content type line 23
PMID 38109906
PQID 2903859403
PQPubID 23479
ParticipantIDs proquest_miscellaneous_2903859403
pubmed_primary_38109906
PublicationCentury 2000
PublicationDate 2024-05-01
PublicationDateYYYYMMDD 2024-05-01
PublicationDate_xml – month: 05
  year: 2024
  text: 2024-05-01
  day: 01
PublicationDecade 2020
PublicationPlace Germany
PublicationPlace_xml – name: Germany
PublicationTitle Thrombosis and haemostasis
PublicationTitleAlternate Thromb Haemost
PublicationYear 2024
Score 2.4660554
SecondaryResourceType review_article
Snippet Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a highly prothrombotic reaction to COVID-19 (coronavirus disease 2019) adenoviral vector vaccines....
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 423
SubjectTerms Anticoagulants - adverse effects
Case Reports as Topic
COVID-19 - complications
COVID-19 Vaccines - adverse effects
Hemorrhage
Humans
Platelet Factor 4 - immunology
Risk Factors
SARS-CoV-2 - immunology
Sinus Thrombosis, Intracranial - etiology
Thrombosis - etiology
Venous Thrombosis
Title Thrombosis and Bleeding in Patients with Vaccine-Induced Immune Thrombotic Thrombocytopenia: A Systematic Review of Published Cases
URI https://www.ncbi.nlm.nih.gov/pubmed/38109906
https://www.proquest.com/docview/2903859403
Volume 124
WOSCitedRecordID wos001126792000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1JS8QwFA7qePDigtu4EcFrmLbptIkXGQdFDw4DjjK3kuUVC9qO01Hw7B83r4ueBMFL6SWlJC95y_fyfYSccaNjxblhnIfcJSihx4QJgPnGExacQUepqsQm4tFITKdy3BTcyqatsj0Tq4PaFgZr5L1AIoYlQ49fzF4ZqkYhutpIaCyTDnehDFp1PK1E6Ppu_0dCTluexn6_V7IKavbjGO9P_h5RVp7leuO__7RJ1puYkg5qI9giS5Bvk8_J07x40UWZlVTlll4-136KZjkd12SqJcUqLH1UBtF1hioeBiy9xSsjQJvx7pvtq_lYoNhWps7pgN5_U0DTGl-gRUrbJntLh847ljvk4fpqMrxhjeICM5zzBQOrQIIvjQ7S1Fe-Ui5DcRmkLwGQWc26lYu0C9JAKmX8QHkoGYok7sKaOLXBLlnJixz2CbU6jPtxgAEGhFpIpa3wLEQaIqGVEV1y2s5p4iwaYQqVQ_FWJj-z2iV79cIks5p6I0E-Muc_o4M_jD4ka4GLQOruxCPSSd1-hmOyat4XWTk_qUzFPUfjuy_8K8zc
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Thrombosis+and+Bleeding+in+Patients+with+Vaccine-Induced+Immune+Thrombotic+Thrombocytopenia%3A+A+Systematic+Review+of+Published+Cases&rft.jtitle=Thrombosis+and+haemostasis&rft.au=Clerici%2C+Bianca&rft.au=Pontisso%2C+Eleonora&rft.au=Aloise%2C+Chiara&rft.au=Peroni%2C+Benedetta&rft.date=2024-05-01&rft.eissn=2567-689X&rft.volume=124&rft.issue=5&rft.spage=423&rft_id=info:doi/10.1055%2Fs-0043-1777134&rft_id=info%3Apmid%2F38109906&rft_id=info%3Apmid%2F38109906&rft.externalDocID=38109906
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2567-689X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2567-689X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2567-689X&client=summon